Status:
COMPLETED
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
Lead Sponsor:
Ayman Saad
Conditions:
Hematologic Neoplasms
Graft-Versus-Host Disease
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha ...
Detailed Description
Transplant patients participating in this clinical trial will receive one of 3 standard pre-transplant chemotherapy preparative regimens as appropriate for their specific disease. They will then recei...
Eligibility Criteria
Inclusion
- Neoplastic hematological disorder with indication of allogeneic transplant
- No available suitable HLA-matched donor
- Adequate cardiac, pulmonary, renal, and hepatic function
- Karnofsky performance status score greater than or equal to 70%
Exclusion
- Medication non-compliance
- No appropriate caregiver identified
- Uncontrolled medical or psychiatric disorder
- Active central nervous system (CNS) neoplastic involvement
- Known allergy to Dimethyl Sulfoxide
- HIV1 or HIV2 positive
- Pregnant or breastfeeding
Key Trial Info
Start Date :
October 9 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 13 2018
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT02193880
Start Date
October 9 2014
End Date
March 13 2018
Last Update
April 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Medical Center (University of Alabama at Birmingham)
Birmingham, Alabama, United States, 35233